PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
20 July 2022, 07:00 CET
Company’s cash runway extended into Q3 2023
Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI (UK) Limited (“Kreos”). Proceeds from the loan will be used to finance general working capital requirements. The loan facility agreement allows the Company to request on an uncommitted basis additional loans of up to EUR 10 million at a later date.
Ian Crosbie, CEO of Sequana Medical, said: “We are delighted to execute this loan facility that extends our cash runway into Q3 2023 and will help us reach key milestones for both…
